Related Experiment Videos
Population screening for neonatal liver disease: potential for a community-based programme.
J E Powell1, S Keffler, D A Kelly
1Department of Public Health and Epidemiology, University of Birmingham, UK.
Journal of Medical Screening
|October 17, 2003
Summary
A community screening program using conjugated bilirubin in blood effectively detects neonatal liver disease. This approach shows high sensitivity and specificity, potentially improving infant outcomes.
Area of Science:
- Neonatology
- Hepatology
- Public Health Screening
Background:
- Neonatal liver disease requires early detection for improved outcomes.
- Current screening methods may not be universally effective or accessible.
Purpose of the Study:
- To evaluate a community-based screening program for neonatal liver disease.
- To assess the utility of conjugated bilirubin quantitation in blood for this purpose.
Main Methods:
- A prospective cohort study analyzed spare plasma from neonatal screening specimens.
- Babies with elevated conjugated bilirubin levels (>18 mumol/l and >20% of total bilirubin) were followed up.
- 27,654 community-born neonates and 2,425 hospitalized neonates were tested.
Main Results:
- The screening test demonstrated high sensitivity (100%) and specificity (99.6%) for neonatal liver disease.
- 11 out of 12 infants with persistently abnormal results were diagnosed with liver conditions, including neonatal hepatitis and biliary atresia.
- 84.7% of specimens were analyzed, with common reasons for exclusion being hemolysis and insufficient sample volume.
Conclusions:
- Conjugated bilirubin in plasma is a reliable marker for detecting neonatal liver disease.
- A population screening program using this method can enhance infant survival and quality of life.
- Adaptation of the method for dried blood spots is crucial for practical implementation in neonatal screening programs.